Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT03079141
SPECT
Half-dose photodynamic therapy versus eplerenone treatment in chronic central
serous chorioretinopathy.
Type: Interventional
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: NA
Inclusion
- Opening Date: 2017-02-20
- Closing Date: 2019-02-20
Criteria
Inclusion: chronic central serous chorioretinopathy, no steroid use, duration < 18 months
Exclusion: steroid use, duration > 18 months, signs of other diagnosis, previous treatment
Children: Yes
Adults: Yes
Funder Type: other
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
